MetaCap

Alto Neuroscience (ANRO) vs Nektar Therapeutics (NKTR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alto Neuroscience (ANRO) has outperformed Nektar Therapeutics (NKTR) over the past year, gaining 91.5% versus a loss of 44.4%. Nektar Therapeutics is the larger company by market cap ($1.03 billion vs $1.02 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANRO+91.47%NKTR-44.36%
+188%+66%-55%
Nov 21, 20251 yearNov 20, 2026
ANRO+22.56%NKTR+259.52%
+1046%+450%-145%
Jan 29, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANRO versus NKTR key metrics
MetricANRONKTR
Share price$25.37$30.20
Market cap$1.02B$1.03B
1-day change-4.30%-7.19%
YTD return+42.53%-28.57%
1-year return+91.47%-44.36%
5-year return—-82.04%
EPS (TTM)$-2.32$-22.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$55.23M
Revenue growth (YoY)—-43.89%
Net income (latest FY)$-63.24M$-164.08M
Gross margin—100.00%
Operating margin—-253.66%
Net margin—-297.07%
52-week high$37.48$109.00
52-week low$12.51$30.13
Distance from 52-week high-32.31%-72.29%
Analyst consensusstrong_buybuy
Avg. price target upside+52.42%+336.82%
Average volume614.92K1.12M
Shares outstanding40.11M34.21M
Employees6863
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANRO has outperformed NKTR by 135.8 percentage points over the past year.

About Alto Neuroscience

ANRO stock →

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees

About Nektar Therapeutics

NKTR stock →

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

ANRO vs NKTR FAQ

Which is bigger, Alto Neuroscience or Nektar Therapeutics?

Nektar Therapeutics (NKTR) is larger, with a market capitalization of $1.03B compared with $1.02B for Alto Neuroscience (ANRO).

Which stock has performed better over the past year, ANRO or NKTR?

ANRO returned +91.47% over the past 12 months, compared with -44.36% for NKTR (price return, excluding dividends). Past performance does not predict future results.

Are Alto Neuroscience and Nektar Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons